PMC:7546122 / 4122-4692 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T17","span":{"begin":60,"end":66},"obj":"Body_part"},{"id":"T18","span":{"begin":168,"end":174},"obj":"Body_part"},{"id":"T19","span":{"begin":241,"end":246},"obj":"Body_part"},{"id":"T20","span":{"begin":423,"end":425},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma61898"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":241,"end":246},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":105,"end":113},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T35","span":{"begin":18,"end":19},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":60,"end":66},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T37","span":{"begin":168,"end":174},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T38","span":{"begin":241,"end":246},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T39","span":{"begin":241,"end":246},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T40","span":{"begin":460,"end":466},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T41","span":{"begin":528,"end":529},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":0,"end":17},"obj":"Sentence"},{"id":"T25","span":{"begin":18,"end":130},"obj":"Sentence"},{"id":"T26","span":{"begin":131,"end":435},"obj":"Sentence"},{"id":"T27","span":{"begin":436,"end":570},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"98","span":{"begin":105,"end":115},"obj":"Species"},{"id":"99","span":{"begin":500,"end":504},"obj":"Chemical"}],"attributes":[{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"IVIG Preparations\nA total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints)."}